CClinicalTrials.gg
RecruitingNCT03276923MADRAUpdated Jan 8, 2026

Maternal Autoimmune Disease Research Alliance (MADRA) Registry

An observational study in Autoimmune Diseases, Pregnancy Related and Systemic Lupus Erythematosus, sponsored by Duke University. Recruiting at 1 site in United States. Open to female participants, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-08.

Sponsored by Duke University · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Sex
Female
01

Study summary

This multi-site registry, centered at Duke University, will enroll pregnant women with autoimmune and rheumatologic diseases.

The main goal of MADRA is to identify ways to improve the health of women with rheumatic diseases and their babies during pregnancy.

Prior studies demonstrate the importance of increase inflammation prior to and during pregnancy on these outcomes. The future research will seek to better define these risk factors and to identify ways to may improve them.

Read the detailed description

At each site, the patients will be under the care of the participating rheumatologist and their local obstetrician during the pregnancy. This is a natural-history study and will not include medications, laboratory testing, or procedures outside of the standard of care.

Management of the rheumatologic disease will be directed based on patient needs by the local rheumatologist and obstetrician. Enrollment in the registry will not dictate specific therapy. The Registry will include data from each office visit during pregnancy and up to 12 months after delivery.

The registry will be ongoing, with periodic analysis of clinical data samples as specific studies are approved.

Enrollment in the registry does not significantly increase risks for a patient.

02

Conditions studied

  • Autoimmune Diseases
  • Pregnancy Related
  • Systemic Lupus Erythematosus
  • Cutaneous Lupus
  • Rheumatoid Arthritis
  • Sjogren's Syndrome
  • Scleroderma
03

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Women who have been diagnosed with an autoimmune disease or a rheumatic condition.

Inclusion criteria

  • Desire for pregnancy within 6 months or currently pregnant
  • Women with systemic autoimmune disease, including:
  • Lupus (systemic lupus erythematosus or cutaneous lupus)
  • Antiphospholipid Syndrome or positive antiphospholipid antibodies
  • Rheumatoid Arthritis
  • Scleroderma (systemic sclerosis)
  • Sjogren's Syndrome
  • Inflammatory Arthritis (including Psoriatic Arthritis and Ankylosing Spondylitis)
  • Undifferentiated Connective Tissue Disease (UCTD)
  • Vasculitis
  • Myositis (Polymyositis or Dermatomyositis)
  • Positive Ro/SSA or La/SSB antibodies

Exclusion criteria

Exclusion Criteria:

  • Unable to speak English
  • Unable to provide informed consent
  • Unable to travel to Duke University for follow-up visits
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Target follow-up
100 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Maternal Autoimmune Disease ReseArch (MADRA) Registry

    Women with autoimmune diseases who are pregnant

05

What researchers measure

Primary outcomes

  1. Risk factors associated with poor pregnancy outcomes as measured by the MADRA-DAP questionnaire.

    The investigators will ask the participants questions from the MADRA-DAP questionnaire to determine poor pregnancy outcomes.

    Time frame: up to 10 years

06

Study locations

1 of 1 sites recruiting
07

Registry details

Key details

Study ID
NCT03276923
Lead sponsor
Duke University
Responsible party
Sponsor
First posted
Sep 8, 2017
Start date
Jan 1, 2018
Primary completion
Jan 1, 2027 (estimated)
Completion
Jan 1, 2027 (estimated)
Last update
Jan 8, 2026

Study contacts

Laura Neil
Contact
laura.k.neil@duke.edu
919 684 8936
Edna Scarlett
Contact
edna.scarlett@duke.edu
919-684-6150
Megan EB Clowse, MD, MPH
principal investigator · Duke Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion